Neumora Therapeutics, Inc. Presents Corporate Presentation at J.P. Morgan Healthcare Conference

Neumora Therapeutics, Inc., a Delaware-based company listed on the Nasdaq Global Select Market under the ticker symbol “NMRA,” recently disclosed its latest developments in a Form 8-K filing with the Securities and Exchange Commission (SEC) on January 13, 2025. The company shared details about its participation in the 43rd Annual J.P. Morgan Healthcare Conference, where it showcased its corporate presentation.

As per the 8-K filing, Neumora Therapeutics made public a corporate presentation during their engagements with investors and analysts at the conference. The presentation, dated January 2025, outlines the company’s strategic goals and plans for advancing neuroscience drug development through innovative therapies. The document, labeled as Exhibit 99.1, serves as a reference to the information shared during the event.

In compliance with the Form 8-K disclosure requirements, the company stated that the information provided in the presentation and the filing is not to be considered as “filed” under the Securities Exchange Act of 1934. It further clarified that the data does not bear any legal liabilities, under Section 18 of said Act or Sections 11 and 12(a)(2) of the Securities Act of 1933. Neumora emphasized that the information in the presentation is not meant for integration by reference into future SEC filings.

The filing also included an exhibit (Exhibit 104) containing a Cover Page Interactive Data File, embedded within the Inline XBRL document.

Neumora’s presentation underscored its pursuit of redefining drug development in the neuroscience domain, aiming to introduce novel therapies for improved patient outcomes in brain-related illnesses. The company highlighted its robust pipeline, financial stability, and a team committed to maximizing success with a proprietary approach.

Specific program focuses mentioned in the presentation include:

1. Navacaprant addressing Major Depressive Disorder (MDD) and Bipolar Depression.
2. NMRA-511 targeting Agitation in Alzheimer’s Disease.
3. NMRA-M4R and NMRA-NMDA tackling Schizophrenia.
4. Various programs addressing Parkinson’s Disease, ALS, and other neurodegenerative conditions.

Neumora’s presentation emphasized the significant market opportunities, therapeutic potentials, innovative mechanisms of action, and intellectual property strength behind its drug development initiatives.

The company’s leadership, led by executives like Co-Founder and Executive Chairman Paul L. Berns, Chief Executive Officer Henry Gosebruch, and Chief Financial Officer Joshua Pinto, underscores Neumora’s commitment to advancing cutting-edge neuroscience solutions to address critical population health challenges.

For detailed insights and projections shared in the corporate presentation, interested parties can refer to the full document filed with the SEC by Neumora Therapeutics, Inc. as per the 8-K disclosure.

The article has been prepared based on the official filing provided by Neumora Therapeutics, Inc. and serves to inform readers about the latest developments from the company in the healthcare sector.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Neumora Therapeutics’s 8K filing here.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.